Futura Medical lifts full-year revenue forecast ahead of strategic review

Futura Medical expects 2025 revenue of £1.7m, above prior guidance, and ended the year with £3.4m net cash following a £2.75m equity raise in November. The company anticipates a ~£300k tax credit refund and a contingent US$2.5m milestone from Haleon (dependent on a US patent grant for lead product Eroxon), and says current cash plus expected receipts and ongoing sales support operations to December 2026. A strategic review is underway and due to conclude in Q1 2026 with findings published alongside full-year results in mid-April; Eroxon remains available OTC in several European markets.

Analysis

Market structure: Futura (AIM:FUM / OTC:FAMDF) is a niche consumer-health winner if the US patent is granted and the US$2.5m Haleon milestone is paid, improving runway to ~£5–6m (cash £3.4m + milestone ~£2m + £0.3m tax credit) and supporting ops through Dec 2026. Competitors in OTC ED treatments see limited immediate pricing pressure—this is a localized product/portfolio uplift rather than a market-wide disruption; Haleon (HLN) stands to gain distribution optionality with low incremental risk. Cross-asset effects are minor: no material bond impact, likely low implied volatility in options due to illiquidity, and modest FX exposure from a USD milestone (sensitivity ~£0.01/US$ moves on reported cash).

Risk assessment: Key tail risks are patent refusal or successful challenge (binary, high-impact) and a strategic review that yields no buyer or forces dilutive equity raising; probability moderate in 6–12 months. Immediate (days) risk: headline disappointment around strategic review timing; short-term (weeks/months): patent grant timing and receipt of Haleon payment H1 2026; long-term (quarters): commercialization scale or M&A outcome. Hidden dependency: milestone appears contingent strictly on US patent grant—contract wording could allow clawbacks or timing delays. Catalysts: patent grant decision, mid-April full-year results/strategic review publication, and Haleon payment timing.

Trade implications: Small, event-driven long with strict sizing—FUM is a binary micro-cap: consider 1–2% portfolio long via AIM:FUM or OTC:FAMDF, staggered 50/50 now vs post-April results; exit triggers: no patent grant by 30 June 2026 or revised runway <3 months. If options/liquidity permit, pair long equity with a put spread (6–9 month buy one 50% OTM put, sell one 70% OTM put) to cap downside while funding premium. Avoid directional positions in HLN; use allocation to small-cap healthcare M&A/ID event funds instead.

Contrarian angle: Market likely underprices strategic-review outcomes—historical small-pharma trades show takeout multiples of 3–8x revenue for branded OTC assets; with £1.7m revenue a sale could imply meaningful upside (target >2–4x current share price). Conversely, consensus may underweight patent/legal timing risk—if patent delayed beyond H1 2026, downside could be >50% and force dilution. Watch for non-linear outcomes: a licensing deal with tiered royalties would de-risk equity more than the headline milestone suggests.

Key Decisions for Investors

• Establish a small, staged long position (1–2% portfolio) in AIM:FUM or OTC:FAMDF: allocate 50% now and 50% after the strategic review/full-year results mid-April 2026; target 100–300% upside if a sale/licensing is announced, and set a hard cut at 40% loss or if company revises runway to <3 months.
• If liquid options exist, implement a protective put-spread for the position: buy a 6–9 month put ~50% OTM and sell a 6–9 month put ~70% OTM to cap downside while reducing premium; limit net premium to <2% of position value.
• Avoid directional positions in HLN; instead, redeploy capital into event-driven small-cap healthcare M&A exposure or ETFs if seeking sector play. Monitor three triggers before adding: (1) patent grant notice, (2) strategic review outcome mid-April 2026, (3) Haleon milestone payment receipt by 30 June 2026—if any fail, reduce/exit position.